Bach1 derepression is neuroprotective in a mouse model of Parkinson’s disease

Manuj Ahuja,Navneet Ammal Kaidery,Otis C. Attucks,Erin McDade,Dmitry M. Hushpulian,Arsen Gaisin,Irina Gaisina,Young Hoon Ahn,Sergey Nikulin,Andrey Poloznikov,Irina Gazaryan,Masayuki Yamamoto,Mitsuyo Matsumoto,Kazuhiko Igarashi,Sudarshana M. Sharma,Bobby Thomas
DOI: https://doi.org/10.1073/pnas.2111643118
IF: 11.1
2021-11-05
Proceedings of the National Academy of Sciences
Abstract:Significance The Keap1-Nrf2 signaling pathway is a promising therapeutic target for Parkinson’s disease (PD). Canonical Nrf2 activators targeting Keap1 thiols are known to be preventive but never effectively cure chronic neurodegeneration because of their electrophilic nature, resulting in nonspecific reactions with active cysteine residues in a variety of cellular proteins. We show that genetic and pharmacologic inhibition of the Nrf2 repressor Bach1 in a posttreatment regimen of experimental PD is neuroprotective by up-regulating Bach1-targeted pathways involving both Nrf2-dependent antioxidant response element (ARE) and non-ARE genes. Inhibition of Bach1 by a nonelectrophilic substituted benzimidazole is a promising therapeutic approach for PD.
multidisciplinary sciences
What problem does this paper attempt to address?